scholarly journals Response to duloxetine in chronic low back pain: exploratory post hoc analysis of a Japanese Phase III randomized study

2017 ◽  
Vol Volume 10 ◽  
pp. 2157-2168 ◽  
Author(s):  
Toshinaga Tsuji ◽  
Naohiro Itoh ◽  
Mitsuhiro Ishida ◽  
Toshimitsu Ochiai ◽  
Shin-ichi Konno
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Randomized Study ◽  
Phase Iii ◽  
Low Back ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Physicians Experience with and Expectations of the Safety and Tolerability of WHO-Step III Opioids for Chronic (Low) Back Pain: Post Hoc Analysis of Data from a German Cross-Sectional Physician Survey

2015 ◽  
Vol 2015 ◽  
pp. 1-8
Author(s):  
Michael A. Ueberall ◽  
Alice Eberhardt ◽  
Gerhard H. H. Mueller-Schwefe
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Daily Life ◽  
Daily Practice ◽  
Low Back ◽  
Cross Sectional ◽  
Post Hoc Analysis ◽  
Analgesic Effects ◽  
Post Hoc

Objective. To describe physicians’ daily life experience with WHO-step III opioids in the treatment of chronic (low) back pain (CLBP). Methods. Post hoc analysis of data from a cross-sectional online survey with 4.283 Germany physicians. Results. With a reported median use in 17% of affected patients, WHO-step III opioids play a minor role in treatment of CLBP in daily practice associated with a broad spectrum of positive and negative effects. If prescribed, potent opioids were reported to show clinically relevant effects (such as ≥50% pain relief) in approximately 3 of 4 patients (median 72%). Analgesic effects reported are frequently related with adverse events (AEs). Only 20% of patients were reported to remain free of any AE. Most frequently reported AE was constipation (50%), also graded highest for AE-related daily life restrictions (median 46%). Specific AE countermeasures were reported to be necessary in approximately half of patients (median 45%); nevertheless AE-related premature discontinuation rates reported were high (median 22%). Fentanyl/morphine were the most/least prevalently prescribed potent opioids mentioned (median 20 versus 8%). Conclusion. Overall, use of WHO-step III opioids for CLBP is low. AEs, especially constipation, are commonly reported and interfere significantly with analgesic effects in daily practice. Nevertheless, beneficial effects outweigh related AEs in most patients with CLBP.

Onset of Response with Duloxetine Treatment in Patients with Osteoarthritis Knee Pain and Chronic Low Back Pain: A Post Hoc Analysis of Placebo-Controlled Trials

2014 ◽  
Vol 36 (4) ◽  
pp. 544-551 ◽  
Author(s):  
Owen D. Williamson ◽  
Melissa Schroer ◽  
Dustin D. Ruff ◽  
Jonna Ahl ◽  
Anthony Margherita ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Knee Pain ◽  
Chronic Low Back Pain ◽  
Controlled Trials ◽  
Low Back ◽  
Post Hoc Analysis ◽  
Osteoarthritis Knee ◽  
Post Hoc

scholarly journals Aquatic and land aerobic training for patients with chronic low back pain: a randomized study

2019 ◽  
Vol 20 (1) ◽  
pp. 1-8
Author(s):  
Ana Carolina Kanitz ◽  
Bruna Machado Barroso ◽  
Guano Zambelli Barbosa ◽  
Andre Ivaniski Mello ◽  
Natalia Carvalho Bagatini ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Aerobic Training ◽  
Randomized Study ◽  
Low Back

scholarly journals Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Vladimir Skljarevski ◽  
Peng Liu ◽  
Shuyu Zhang ◽  
Jonna Ahl ◽  
James M. Martinez
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Pooled Analysis ◽  
Analysis Of Covariance ◽  
Low Back ◽  
Substantial Evidence ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Post Hoc

This subgroup analysis assessed the efficacy of duloxetine in patients with chronic low back pain (CLBP) who did or did not use concomitant nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen (APAP). Data were pooled from two 13-week randomized trials in patients with CLBP who were stratified according to NSAID/APAP use at baseline: duloxetine NSAID/APAP user (), placebo NSAID/APAP user (), duloxetine NSAID/APAP nonuser (), and placebo NSAID/APAP nonuser (). NSAID/APAP users were those patients who took NSAID/APAP for at least 14 days per month during 3 months prior to study entry. An analysis of covariance model that included therapy, study, baseline NSAID/APAP use (yes/no), and therapy-by-NSAID/APAP subgroup interaction was used to assess the efficacy. The treatment-by-NSAID/APAP use interaction was not statistically significant () suggesting no substantial evidence of differential efficacy for duloxetine over placebo on pain reduction or improvement in physical function between concomitant NSAID/APAP users and non-users.

scholarly journals Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study

2021 ◽  
Author(s):  
Shin-ichi Konno ◽  
Takuya Nikaido ◽  
John D Markman ◽  
Makoto Ohta ◽  
Toshiya Machida ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Japanese Patients ◽  
Phase Iii ◽  
Low Back ◽  
Clinical Trial Registration ◽  
Safety Event ◽  
And Function

Aim & methods: This trial investigated long-term (56-week treatment/24-week follow-up) use of subcutaneous tanezumab (5 or 10 mg every 8 weeks) or oral celecoxib (200 mg/day) in Japanese patients with chronic low back pain. Results & conclusion: Tanezumab safety was consistent with previous studies, except overall adverse events (tanezumab 5 mg = 63.0%, tanezumab 10 mg = 54.8%, celecoxib = 67.4%) and events of abnormal peripheral sensation (tanezumab 5 mg = 9.8%, tanezumab 10 mg = 4.3%, celecoxib = 4.3%) were more frequent with 5 mg than 10 mg tanezumab. Joint safety event rates were 1.1% for tanezumab 5 mg, 2.2% for tanezumab 10 mg and 0% for celecoxib. All treatments improved pain and function throughout the treatment period. Clinical trial registration number: NCT02725411

Effect of low-dose amitriptyline on low back pain with a neuropathic component: a post hoc analysis

2021 ◽  
Author(s):  
Donna M. Urquhart ◽  
Anita E. Wluka ◽  
Stephane Heritier ◽  
Chris Fong ◽  
Yuanyuan Wang ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Low Dose ◽  
Low Back ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document